A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

Clinical Trial ID NCT00056836

PubWeight™ 60.31‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00056836

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 30.63
2 Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 19.42
3 Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011 2.43
4 Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007 1.89
5 Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010 1.49
6 Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013 1.19
7 Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014 0.99
8 Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 2010 0.98
9 Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. J Ophthalmol 2012 0.90
10 Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Am J Ophthalmol 2011 0.88
11 Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology 2012 0.84
12 Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013 0.83
13 Patient-reported outcomes among sham vs no-treatment controls from randomized trials. Arch Ophthalmol 2011 0.81
14 Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010 0.81
15 Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Adv Ther 2016 0.75
16 A new epidemiological aid in deciding whether to continue or stop a treatment. Invest Ophthalmol Vis Sci 2012 0.75
Next 100